SCHEMBL254754

SCHEMBL254754

CCOc1ccccc1C(C)C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.54
L3MBTL1 Q9Y468 6/20 0.51
KMT2A Q03164 4/20 0.51
MEN1 O00255 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
RECQL P46063 1/20 0.51
LMNA P02545 2/20 0.50
NISCH Q9Y2I1 1/20 0.50
MAPT P10636 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
GLA P06280 1/20 0.47
ADRB2 P07550 1/20 0.45
ADRB1 P08588 1/20 0.45
ADRB3 P13945 1/20 0.45
CTDSP1 Q9GZU7 1/20 0.45
P2RX3 P56373 1/20 0.45
P2RX2 Q9UBL9 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18309270 0.86 L3MBTL1 (0.60) ALDH1A1L3MBTL1KMT2AMEN1CYP1A2
SCHEMBL11108872 0.86 KMT2A (0.51) ALDH1A1L3MBTL1KMT2AMEN1CYP1A2
SCHEMBL2903384 0.85 L3MBTL1 (0.55) ALDH1A1L3MBTL1KMT2AMEN1CYP1A2
SCHEMBL9226775 0.84 L3MBTL1 (0.58) ALDH1A1L3MBTL1KMT2AMEN1CYP1A2
SCHEMBL23251447 0.83 ALDH1A1 (0.50) ALDH1A1L3MBTL1KMT2ACYP1A2CYP2C19
SCHEMBL8047365 0.83 ALDH1A1 (0.50) ALDH1A1L3MBTL1KMT2ACYP1A2CYP2C19
SCHEMBL2091375 0.83 KMT2A (0.49) ALDH1A1L3MBTL1KMT2AMEN1CYP1A2
SCHEMBL21670118 0.83 ALDH1A1 (0.50) ALDH1A1L3MBTL1KMT2ACYP1A2CYP2C19
SCHEMBL18950277 0.83 ALDH1A1 (0.50) ALDH1A1L3MBTL1KMT2ACYP1A2CYP2C19
SCHEMBL19122587 0.83 L3MBTL1 (0.56) ALDH1A1L3MBTL1KMT2ALMNANISCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2925139-B1 FERMENTED SOIL ADDITIVE LIQUID FERTILISER SYSTEMS PTY LTD (AU) 2025-04-30 EP disclosed
CN-115010584-B Method for synthesizing aromatic ketone by iron-catalyzed oxidation of tertiary carbon bond breaking of benzyl position 南京师范大学 2023-12-12 CN disclosed
US-11820757-B2 Antagonists of the muscarinic acetylcholine receptor M4 VANDERBILT UNIVERSITY (US) 2023-11-21 US disclosed
US-20230364070-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ANTARES THERAPEUTICS, INC. 2023-11-16 US disclosed
US-20230233560-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-07-27 US disclosed
US-20230233560-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-07-27 US disclosed
EP-3686197-B1 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2023-06-21 EP disclosed
US-11643404-B2 Ester substituted ion channel blockers and methods for use Nocion Therapeutics, Inc. (US) 2023-05-09 US disclosed
US-20230135560-A1 GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2023-05-04 US disclosed
US-20230135560-A1 GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2023-05-04 US disclosed
EP-1818340-A1 GLYCOPEPTIDE ANTIBIOTIC MONOMER DERIVATIVES National University Corporation Nagoya University (JP) 2007-08-15 EP disclosed
US-20070149506-A1 Azepine inhibitors of Janus kinases INCYTE CORPORATION 2007-06-28 US disclosed
CN-1950699-A Method for monitoring a polymerization in a three-dimensional sample 3M INNOVATIVE PROPERTIES CO (US) 2007-04-18 CN disclosed
EP-1587850-A1 CURING AGENTS FOR CATIONICALLY CURABLE COMPOSITIONS 3M Innovative Properties Company (US) 2005-10-26 EP disclosed
WO-2004060959-A1 CURING AGENTS FOR CATIONICALLY CURABLE COMPOSITIONS 3M INNOVATIVE PROPERTIES COMPANY (US) 2004-07-22 WO disclosed
EP-1292862-A2 MULTIPASS MULTIPHOTON ABSORPTION METHOD AND APPARATUS 3M Innovative Properties Company (US) 2003-03-19 EP disclosed
CN-1357142-A Optical storage medium 3M INNOVATIVE PROPERTIES CO (US) 2002-07-03 CN disclosed
WO-2001096961-A2 MULTIPASS MULTIPHOTON ABSORPTION METHOD AND APPARATUS 3M INNOVATIVE PROPERTIES COMPANY (US) 2001-12-20 WO disclosed
CN-1074705-C Coated abrastive article and method of making same MINNESOTA MINING & MFG (US) 2001-11-14 CN disclosed
CN-1074637-A Coated abrasive article and preparation method thereof MINNESOTA MINING & MFG (US) 1993-07-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11820757-B2 Antagonists of the muscarinic acetylcholine receptor M4 CHRM2, CHRM3, CHRM4 ALDH1A1 1973/4885L3MBTL1 2243/4885KMT2A 2450/4885
US-20230233560-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1B, SLC26A4 ALDH1A1 3524/4885L3MBTL1 3997/4885KMT2A 3837/4885
US-20230135560-A1 GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC1R, MC3R, MC2R ALDH1A1 2971/4885L3MBTL1 4621/4885KMT2A 1137/4885
US-20230364070-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ERBB2, EGFR, ERBB3 ALDH1A1 2594/4885L3MBTL1 4678/4885KMT2A 3203/4885
US-11643404-B2 Ester substituted ion channel blockers and methods for use TRPV1, TRPA1, TRPV2 ALDH1A1 1138/4885L3MBTL1 4810/4885KMT2A 2763/4885
US-20070149506-A1 Azepine inhibitors of Janus kinases JAK1, JAK3, JAK2 ALDH1A1 3705/4885L3MBTL1 2859/4885KMT2A 521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.